Travere Therapeutics (TVTX) News Today $17.72 -0.75 (-4.06%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Piper Sandler Forecasts Strong Price Appreciation for Travere Therapeutics (NASDAQ:TVTX) StockPiper Sandler increased their price target on Travere Therapeutics from $12.00 to $22.00 and gave the company a "neutral" rating in a research report on Thursday.November 14 at 10:14 AM | marketbeat.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 13, 2024 | globenewswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives $21.85 Average Price Target from AnalystsNovember 13, 2024 | americanbankingnews.com3 Under-the-Radar Healthcare Companies (TVTX)While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains.November 11, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXNovember 10, 2024 | prnewswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Rating of "Moderate Buy" from AnalystsShares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the thirteen analysts that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and eleven have giveNovember 10, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Reaches New 12-Month High - Here's What HappenedTravere Therapeutics (NASDAQ:TVTX) Hits New 12-Month High - Here's What HappenedNovember 8, 2024 | marketbeat.comTravere Therapeutics Announces Pricing of Public Offering of Common StockNovember 7, 2024 | globenewswire.comTravere Therapeutics Announces Proposed Public Offering of Common StockNovember 7, 2024 | globenewswire.comStifel Nicolaus Remains a Hold on Travere Therapeutics (TVTX)November 5, 2024 | markets.businessinsider.comTravere Therapeutics to Present at Upcoming Investor ConferencesNovember 4, 2024 | globenewswire.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by Emerald Advisers LLCEmerald Advisers LLC boosted its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 19.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,960,659 shares of the company's stock after purchaNovember 3, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXNovember 2, 2024 | prnewswire.comTravere Therapeutics (NASDAQ:TVTX) Given New $27.00 Price Target at ScotiabankScotiabank raised their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the stock a "sector outperform" rating in a research report on Friday.November 1, 2024 | marketbeat.comTravere Therapeutics Inc (TVTX) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amid ...November 1, 2024 | finance.yahoo.comTravere Therapeutics Boosts Sales with FILSPARI ApprovalNovember 1, 2024 | markets.businessinsider.comTravere Therapeutics Inc (TVTX) Q3 2024 Earnings Report Preview: What to ExpectOctober 31, 2024 | finance.yahoo.comTravere Therapeutics Reports Third Quarter 2024 Financial ResultsOctober 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics Amid Promising Filspari Efficacy in Treating IgAN and FSGSOctober 29, 2024 | markets.businessinsider.comJ.P. Morgan Keeps Their Buy Rating on Travere Therapeutics (TVTX)October 29, 2024 | markets.businessinsider.comSemanteon Capital Management LP Purchases Shares of 36,699 Travere Therapeutics, Inc. (NASDAQ:TVTX)Semanteon Capital Management LP acquired a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 36,699 shares of the company's stock, valuedOctober 29, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $19.23 Million Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)Assenagon Asset Management S.A. decreased its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 37.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,374,522 shares of the company's stock after selliOctober 27, 2024 | marketbeat.comTravere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024October 26, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXOctober 25, 2024 | prnewswire.comTravere Therapeutics (TVTX) Set to Announce Quarterly Earnings on ThursdayTravere Therapeutics (NASDAQ:TVTX) will be releasing earnings before the market opens on Thursday, October 31, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638084)October 24, 2024 | marketbeat.comWells Fargo Upgrades Travere Therapeutics (TVTX)October 22, 2024 | msn.comTravere Therapeutics to Report Third Quarter 2024 Financial ResultsOctober 21, 2024 | globenewswire.comWells Fargo upgrades Travere Therapeutics to Overweight on further upsideOctober 21, 2024 | markets.businessinsider.comTravere Therapeutics (NASDAQ:TVTX) Shares Gap Up - Time to Buy?Travere Therapeutics (NASDAQ:TVTX) Shares Gap Up - Should You Buy?October 21, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Upgraded at Wells Fargo & CompanyWells Fargo & Company raised shares of Travere Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $9.00 to $27.00 in a research report on Monday.October 21, 2024 | marketbeat.comState Street Corp's Strategic Reduction in Travere Therapeutics HoldingsOctober 18, 2024 | finance.yahoo.comTravere Therapeutics (NASDAQ:TVTX) Hits New 1-Year High - Here's WhyTravere Therapeutics (NASDAQ:TVTX) Hits New 1-Year High - Here's What HappenedOctober 17, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXOctober 17, 2024 | prnewswire.comTravere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA NephropathyOctober 17, 2024 | globenewswire.comCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA NephropathyOctober 17, 2024 | prnewswire.comTravere Therapeutics (NASDAQ:TVTX) Research Coverage Started at ScotiabankScotiabank began coverage on Travere Therapeutics in a research report on Wednesday. They set a "sector outperform" rating on the stock.October 16, 2024 | marketbeat.comTravere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024October 14, 2024 | globenewswire.comAnalysts Offer Predictions for Travere Therapeutics, Inc.'s Q4 2025 Earnings (NASDAQ:TVTX)Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Analysts at Leerink Partnrs lifted their Q4 2025 EPS estimates for Travere Therapeutics in a research note issued to investors on Friday, October 11th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earningsOctober 14, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Sees Significant Decline in Short InterestTravere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) saw a large decline in short interest during the month of September. As of September 30th, there was short interest totalling 6,960,000 shares, a decline of 19.6% from the September 15th total of 8,660,000 shares. Based on an average daily trading volume, of 1,660,000 shares, the short-interest ratio is currently 4.2 days.October 13, 2024 | marketbeat.comTVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the FirmOctober 13, 2024 | globenewswire.comTravere Therapeutics (NASDAQ:TVTX) Trading Down 4% - Here's What HappenedTravere Therapeutics (NASDAQ:TVTX) Shares Down 4% - Should You Sell?October 11, 2024 | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) to Post FY2026 Earnings of $2.81 Per Share, Wedbush ForecastsTravere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Equities researchers at Wedbush upped their FY2026 earnings per share estimates for Travere Therapeutics in a report released on Wednesday, October 9th. Wedbush analyst L. Chico now forecasts that the company will post earnings of $2.81 perOctober 11, 2024 | marketbeat.comEvercore ISI Keeps Their Buy Rating on Travere Therapeutics (TVTX)October 10, 2024 | markets.businessinsider.comTVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the FirmOctober 10, 2024 | prnewswire.comTravere Therapeutics Inc (TVTX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ...October 10, 2024 | finance.yahoo.comBuy Rating for Travere Therapeutics: Promising FSGS Treatment and Favorable Regulatory OutlookOctober 10, 2024 | markets.businessinsider.comTravere Therapeutics: Hold Rating Amid FDA Approval Uncertainties and PARASOL Meeting InsightsOctober 10, 2024 | markets.businessinsider.comFY2025 EPS Estimates for Travere Therapeutics, Inc. Boosted by Analyst (NASDAQ:TVTX)Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Stock analysts at Wedbush lifted their FY2025 EPS estimates for Travere Therapeutics in a report released on Wednesday, October 9th. Wedbush analyst L. Chico now expects that the company will post earnings per share of $1.03 for the year, uOctober 10, 2024 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) PT Raised to $20.00 at Bank of AmericaBank of America boosted their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company a "buy" rating in a research report on Wednesday.October 9, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXOctober 9, 2024 | prnewswire.com Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. TVTX Media Mentions By Week TVTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVTX News Sentiment▼0.740.56▲Average Medical News Sentiment TVTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVTX Articles This Week▼85▲TVTX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Harrow News Today Rigel Pharmaceuticals News Today Omeros News Today Nuvalent News Today Arcellx News Today ADMA Biologics News Today Krystal Biotech News Today Avidity Biosciences News Today BridgeBio Pharma News Today Biohaven News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVTX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
